SQZ Biotechnologies Operating Income 2020-2022 | SQZ

SQZ Biotechnologies operating income from 2020 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
SQZ Biotechnologies Annual Operating Income
(Millions of US $)
2021 $-69
2020 $-51
2019 $-34
SQZ Biotechnologies Quarterly Operating Income
(Millions of US $)
2022-03-31 $-21
2021-12-31 $-12
2021-09-30 $-22
2021-06-30 $-19
2021-03-31 $-15
2020-12-31 $-18
2020-09-30 $-12
2020-06-30 $-10
2020-03-31 $-11
2019-09-30 $-8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.094B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10